Patient-based outcomes using the walking impairment questionnaire for patients with peripheral arterial occlusive disease treated with lipo-PGE 1

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 365-370

  Matsuo, Hiroshi ^a   Shigematsu, Hiroshi ^b  

^a Matsuo Vascular Ultrasound Laboratory   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Intermittent claudication; Lipo PGE1; Peripheral arterial occlusive disease (PAD); Quality of life (QOL); Walking impairment questionnaire (WIQ)

Indexed keywords

ANTITHROMBOCYTIC AGENT; LIPOPROSTAGLANDIN E1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE;

AGED; ANKLE BRACHIAL INDEX; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHLEBITIS; QUESTIONNAIRE; RASH; VASCULAR DISEASE; WALKING DIFFICULTY;

AGED; AGED, 80 AND OVER; ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; DISABILITY EVALUATION; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WALKING;

EID: 75749157006     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0376     Document Type: Article

References (24)

1. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral artery disease on health-related quality of life in the Peripheral Artery Disease Awareness, Risk, and Treatment: New Reseources for Survival (PARTNERS) Program. Vasc Med 2008; 13: 15 - 24.
2. Sakamoto S, Yokoyama N, Tamori Y, Akutsu K, Hashimoto H, Takeshita S. Patients with peripheral artery disease who complete 12-week supervised exercise training program show reduced cardiovascular mortality and morbidity. Circ J 2009; 73: 167 - 173.
3. 2A antagonist sarpogrelate on walking ability in patients with intermittent claudication as measured using the Walking Impairment Questionnaire. Ann Vasc Dis 2008; 1: 102 - 110.
4. Manfredini F, Malagoni AM, Mascoli F, Mandini S, Taddia MC, Basaglia N, et al. Training rather than walking: The test in-train out program for home-based rehabilitation in peripheral arteriopathy. Circ J 2008; 72: 946 - 952.
5. Kinoshita Y, Suzuki T, Hosokawa H, Yokoya K. Usefulness of the Symphony Nitinol Stent for arteriosclerosis obliterans. Circ J 2002; 66: 1000 - 1002.
6. Hoshino J, Ubara Y, Ohara K, Ohta E, Suwabe T, Higa Y, et al. Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). Circ J 2008; 72: 1495 - 1498.
7. Kajiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, Shintani S, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71: 196 - 201.
8. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990; 2: 142 - 152.
9. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP; Vascular Clinical Trialists. Clinical trials for claudication: Assessment of exercise performance, functional status, and clinical end points. Circulation 1995; 92: 614 - 621.
10. Dormandy JA, Rutherford RB; TransAtlantic Inter-Society Consensus Working Group. Management of peripheral arterial disease (PAD). J Vasc Surg 2000; 31: S1 - S296.
11. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1 - S75.
12. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: Associations with the ankle - brachial index and leg symptoms. JAMA 2004; 292: 453 - 461.
13. Nonaka K, Kume N, Urata Y, Seto S, Kohno T, Honda S, et al. Serum levels of S-glutathionylated proteins as a risk marker for arteriosclerosis obliterans. Circ J 2007; 71: 100 - 105.
14. Japanese Circulation Society. Guidelines for Rehabilitation in Patients with Cardiovascular Disease 2007. Kyoto: Japanese Circulation Society, 2007.
15. Ikeda S, Kobayashi M, Shigematsu H. Development of the Japanese version of Walking Improvement Questionnaire. J Jpn Coll Angiol 2005; 45: 233 - 240.
16. Nicolaï SP, Kruidenier LM, Rouwet EV, Graffius K, Prins MH, Teijink JA. The walking impairment questionnaire: An effective tool to assess the effect of treatment in patients with intermittent claudication. J Vasc Surg 2009; 50: 89 - 94.
17. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: Validation of the walking improvement questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998; 28: 1072 - 1081.
18. Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio RD, De Caterina R. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J 2001; 142: 733 - 739.
19. Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J 2003; 145: 330 - 333.
20. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427 - 435.
21. 1 (Alprostadil): The possibility of pharmaceutical angiogenesis therapy. Inflamm Regen 2004; 24: 656 - 660.
22. 1 on angiogenesis in a rat sponge model. Jpn Pharmacol Ther 2001; 29: 733 - 737.
23. Mangiafico RA, Messina R, Attinà T, Dell'Arte S, Giuliano L, Malatino LS. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication. Angiology 2000; 51: 441 - 449.
24. Fukuda S, Esato K. The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. Int Angiol 2004; 23: 238 - 245.